• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• BL Club
• Smartbuy
• Books

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Mr Malvinder Singh and Mr Takashi Shoda (file photo).

Our Bureau

New Delhi, Dec 19 Ranbaxy Laboratories Ltd and Daiichi Sankyo Co Ltd announced the reconstitution of the Indian pharma company’s board of directors.

As part of the restructuring, 10 current directors including Mr Shivinder Mohan Singh, Mr Brian Tempest, Mr Gurcharan Das, Mr Vivek Bharat Ram and Mr Ramesh Adige have resigned.

The new board reflects the changed ownership structure at Ranbaxy, following Daiichi Sankyo’s strategic investment in November 2008. The Japanese pharma major now holds 63.92 per cent of Ranbaxy’s equity share capital.

Mr Takashi Shoda, President and CEO of Daiichi Sankyo, and Mr Tsutomu Une, Senior Executive Officer, have moved in as directors.

Mr Atul Sobti continues as the Chief Operating Officer. The other directors include Mr Anthony Wild, Partner, BOWS Pharmaceuticals AG; Mr Rajesh Shah, Co-chairman and MD, Mukand Ltd; Mr Sunil Godhwani, CEO and MD, Religare Enterprise Ltd; Mr Akhiro Watanabe, Representative Director, GCA Savvian Group; and Mr Balinder Singh Dhillon, an advocate.

Commenting on the restructuring, Mr Shoda said, “These appointments signify both companies’ absolute commitment to driving success for this strategic alliance. I am confident that with the leadership team we now have in place, Ranbaxy will swiftly make a significant contribution to the Daiichi Sankyo Group. I believe this unique hybrid business model allows both companies to fully realise their strengths and will become the standard for growth in the pharmaceutical industry of the future.”

As announced, Mr Malvinder Mohan Singh, CEO and MD, additionally assumes the role of Chairman of the board of directors. Mr Singh has also become a member of the senior global management team of Daiichi Sankyo.

More Stories on : Pharmaceuticals | People | Ranbaxy Laboratories Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line